t2dm

Geranylgeranyl pyrophosphate tetrabutylammonium(1：2) is one of the endogenous cholesterol and intermediates produced by the mevalerate pathway. Geranylgeranyl pyrophosphate tetrabutylammonium(1：2) is the common precursor of diterpenoids, for example, Paclitaxel. It can be used for cancer research.

Nucleoside Derivatives - 5-Modified pyrimidine nucleosides, Protected nucleosides with NH2/OH open

Nucleoside; Used for special nucleoside modifications

T-Type calcium channel inhibitor 2 (compound 6g) is a potent inhibitor of the T-type calcium channel, acting on Cav3.1 (α1G) (IC50: 31.0 μM), Cav3.2 (α1H) (IC50: 83.1 μM), Cav3.3 (α1I) (α1H) ( T-Type calcium channel inhibitor 2 exhibited cytotoxicity against A549 and HCT-116 cells with IC50s of 5.0 and 6.4 μM, respectively.

Nucleoside Derivatives - 5-Modified pyrimidine nucleosides,2’-Modified nucleosides; Protected nucleosides with NH2/OH group

Super-chelating agent& MRI contrast agent

4'-alpha-C-Allyl-2',3'-bis(O-t-butyldimethylsilyl)uridine is a Nucleoside Derivative - 4'-Modified nucleoside; Protected nucleoside w/NH2/OH open.

2',3'-Bis-O-(t-butyldimethylsilyl)-5'-O-(4,4'-dimethyltriphenylmethyl)uridine is a nucleoside Derivative - Other modified nucleoside.

T-2 Toxin (T-2 Mycotoxin) is a fungal secondary metabolite produced by various Fusarium species in feed and grains, which is highly toxic to reproduction and induces a variety of cardiovascular toxicities.T-2 Toxin is an inhibitor of peptidyl transferase (60s ribosomal subunit) binding and protein synthesis. T-2 Toxin is an inhibitor of peptidyl transferase (60s ribosomal subunit) binding and protein synthesis, induces TM4 cell dysfunction via ROS-induced apoptosis, inhibits DNA and RNA synthesis, and increases hepatic lipid peroxidation levels.

2’,3’-Bis-O-(t-butyldimethylsilyl)-N1-methylpseudouridine is a useful organic compound for research related to life sciences and the catalog number is TNU1576.

3,5’-Bis(O-t-butyldimethylsilyl)-2’-O-methyl-5-methyl cytidine, a cytidine analog, inhibits DNA methyltransferases (e.g., Zebularine), exhibiting potential anti-metabolic and anti-tumor activities [1].

N4-Benzoyl-2',3'-di-O-(t-butyldimethylsilyl)-5'-O-(4,4'-dimethoxytrityl)-N4-methylcytidine is a nucleoside Derivative - Other modified nucleoside.

Nucleoside Derivative –4’-Modified nucleosides; Protected nucleosides with NH2/OH group

3'-O-(t-Butyldimethylsilyl)-2'-deoxyadenosine is a Nucleoside Derivative - Protected nucleoside with NH2/OH group open.

5'-O-t-Butyldimethylsilyl 2'-deoxy-5-iodo-uridine is a Halo-nucleoside; 2'-deoxy nucleoside.

1,4-Anhydro-2-de oxy-3-O-(t-butyldiphenylsilyl-D-erythro-pent-1-enitol is a useful organic compound for research related to life sciences. The catalog number is TNU1443 and the CAS number is 130277-32-6.

t-Butyl (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-isopropylidenedioxy-6-heptenoate is a useful organic compound for research related to life sciences. The catalog number is T66069 and the CAS number is 147489-06-3.

3'-O-(t-Butyldimethylsilyl)-2'-O-(2-methoxyethyl) uridine is a Nucleoside Derivative - Protected nucleoside w/NH2/OH open; 2'-Modified nucleoside.

2',3'-Bis-(O-t-butyldimethylsilyl)uridine is a Nucleoside Derivative - Protected nucleoside with NH2/OH open.

Nucleoside Derivatives - Fluoro-Modified nucleosides, 2’-Modified nucleosides; Protected nucleosides with NH2/OH group

2',3'-Bis(O-t-butyldimethylsilyl)-4',5'-Didehydro-5'-deoxyuridine is a Nucleoside Derivative - 5'-Modified nucleoside, Didehydro-nucleoside.

1,4-Anhydro-2-deoxy-3,5-bis-O-(t-butyl diphenylsilyl-D-erythro-pent-1-enitol is a useful organic compound for research related to life sciences. The catalog number is TNU1642 and the CAS number is 105930-84-5.

Nucleoside; Used for RNA synthesis and special nucleoside modification

N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine is a Nucleoside Derivative - C-nucleoside; N-Alkylated nucleoside.

T- 2 Tetraol is a T-2 toxin metabolite, and also a trichothecene mycotoxin, with less toxicity and is unable to induce apoptosis.

Methanesulfonato[2-(di-t-butylphosphino)-2'-(N,N-dimethylamino)-1,1'-biphenyl](2'-amino-1,1'-biphenyl-2-yl)palladium(II) is a useful organic compound for research related to life sciences and the catalog number is T67256.

Nucleoside Derivatives - Thio-nucleosides, Protected nucleosides with NH2/OH open

Heterocyclic Compounds - Pyrimidine; Intermediate and Building Blocks - Nucleoside base

Nucleoside Derivatives –2’-Modified nucleosides; 5-Modified pyrimidine nucleosides

3'-O-(t-Butyldimethylsilyl)-2'-O-(2-methoxyethyl)-5-methyluridine is a Nucleoside Derivative - Protected nucleoside w/NH2/OH open; 2'-Modified nucleoside.

Acetonitrilebis[2-diphenylphosphino-6-t-butylpyridine]cyclopentadienylruthenium(II) hexafluorophosphate is a useful organic compound for research related to life sciences and the catalog number is T67238.

2-O-benzoyl-3-O-t-butyldiphenylsilyl-L-threonolactone is a Carbohydrate Derivative.

3'-O-(t-Butyldimethylsilyl)-2'-O-methyluridine is a Nucleoside Derivative - 2'-Modified nucleoside; Protected nucleoside with NH2/OH group.

Nucleoside Derivatives - 4’-Modified nucleosides; Azido nucleosides; Protected nucleosides w/NH2/OH open

Lobeglitazone Sulfate（CKD-501 Sulfate） is a novel thiazolidinedione with anti-inflammatory activity that inhibits LPS-induced NLRP3 inflammasome activation and hepatic inflammation, and can be used in the study of type 2 diabetes mellitus (T2DM).

Albiglutide TFA (782500-75-8 free base) (Albiglutide TFA) is a long acting GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus (T2DM).

GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).

GSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist (pEC50: 7.5). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis.

α-Glucosidase-IN-22 is a selective inhibitor of α-glucosidase (IC50=0.64 μM). α-Glucosidase-IN-22 has antidiabetic activity and has potential in type 2 diabetes (T2DM) studies.

Retagliptin Phosphate (SP 2086) is pharmaceutical composition of DPP-4 inhibitor, for treating type-2 diabetes.

Luseogliflozin (TS 071) hydrate, a second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor, exhibits selective potency and oral activity, with an IC50 of 2.26 nM. This compound is utilized in research for the treatment of type 2 diabetes mellitus (T2DM).

Fazpilodemab (BFKB8488A) is a humanized agonistic bispecific antibody that targets fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. It is utilized in research pertaining to Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) [1].

AZD9977 is a novel, selective modulator of mineralocorticoid receptor .

Trelagliptin succinate (SYR-472 succinate) is a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), being developed for the treatment of type 2 diabetes (T2D).

Trelagliptin (SYR-472) is a highly specific and long-acting DPP-4 inhibitor.

GSK1292263 is a GPR119 agonist and has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.

α-Glucosidase-IN-26 (Compound 7i), with an IC50 value of 4.63 µM, functions as an α-glucosidase inhibitor and is utilized in research related to type 2 diabetes mellitus (T2DM) [1].

INCB13739 is an orally active, potent, selective, and tissue-specific inhibitor of 11β-HSD1 (11β-hydroxysteroid dehydrogenase 1), demonstrating IC50 values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC). It is utilized in research for type 2 diabetes mellitus (T2DM) and obesity [1].

Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (PF-05231023) is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suitable for development as a potential treatment for T2DM.

Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). It is in development for the treatment of type 2 diabetes mellitus (T2DM). It inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.